Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock.

Abstract	The role of drotrecogin alfa (activated) (DAA) in severe sepsis remains controversial and clinicians are unsure whether or not to treat their patients with DAA. In response to a request from the European Medicines Agency, Eli Lilly will sponsor a new placebo-controlled trial and history suggests the results will be subject to great scrutiny. An academic steering committee will oversee the conduct of the study and will write the study manuscripts. The steering committee intends that the study will be conducted with the maximum possible transparency; this includes publication of the study protocol and a memorandum of understanding which delineates the role of the sponsor. The trial has the potential to provide clinicians with valuable data but patients will only benefit if clinicians have confidence in the conduct, analysis and reporting of the trial. This special article describes the process by which the trial was developed, major decisions regarding trial design, and plans for independent analysis, interpretation and reporting of the data.
Authors	Simon Finfer, V Marco Ranieri, B Taylor Thompson, Philip S Barie, Jean-François Dhainaut, Ivor S Douglas, Bengt Gårdlund, John C Marshall, Andrew Rhodes
Journal	Intensive care medicine (Intensive Care Med) Vol. 34 Issue 11 Pg. 1935-47 (Nov 2008) ISSN: 0342-4642 [Print] United States
PMID	18839141 (Publication Type: Journal Article)
Chemical References	Anti-Infective Agents Placebos Protein C Recombinant Proteins drotrecogin alfa activated
Topics	APACHE Anti-Infective Agents (therapeutic use) Clinical Trials, Phase III as Topic (ethics, methods) Drug Industry (ethics) Humans Multicenter Studies as Topic (ethics, methods) Placebos Protein C (therapeutic use) Randomized Controlled Trials as Topic (ethics, methods) Recombinant Proteins (therapeutic use) Research Design Shock, Septic (drug therapy, mortality) Surveys and Questionnaires Treatment Outcome United States (epidemiology) United States Food and Drug Administration

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!